Literature DB >> 29987703

Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal Degradation.

Joanna E Pankiewicz1,2, Sandrine Sanchez1, Kent Kirshenbaum3, Regina B Kascsak4, Richard J Kascsak4, Martin J Sadowski5,6,7.   

Abstract

PrPSc is an infectious and disease-specific conformer of the prion protein, which accumulation in the CNS underlies the pathology of prion diseases. PrPSc replicates by binding to the cellular conformer of the prion protein (PrPC) expressed by host cells and rendering its secondary structure a likeness of itself. PrPC is a plasma membrane anchored protein, which constitutively recirculates between the cell surface and the endocytic compartment. Since PrPSc engages PrPC along this trafficking pathway, its replication process is often referred to as "recycling propagation." Certain monoclonal antibodies (mAbs) directed against prion protein can abrogate the presence of PrPSc from prion-infected cells. However, the precise mechanism(s) underlying their therapeutic propensities remains obscure. Using N2A murine neuroblastoma cell line stably infected with 22L mouse-adapted scrapie strain (N2A/22L), we investigated here the modus operandi of the 6D11 clone, which was raised against the PrPSc conformer and has been shown to permanently clear prion-infected cells from PrPSc presence. We determined that 6D11 mAb engages and sequesters PrPC and PrPSc at the cell surface. PrPC/6D11 and PrPSc/6D11 complexes are then endocytosed from the plasma membrane and are directed to lysosomes, therefore precluding recirculation of nascent PrPSc back to the cell surface. Targeting PrPSc by 6D11 mAb to the lysosomal compartment facilitates its proteolysis and eventually shifts the balance between PrPSc formation and degradation. Ongoing translation of PrPC allows maintaining the steady-state level of prion protein within the cells, which was not depleted under 6D11 mAb treatment. Our findings demonstrate that through disrupting recycling propagation of PrPSc and promoting its degradation, 6D11 mAb restores cellular proteostasis of prion protein.

Entities:  

Keywords:  Endo-lysosomal system; Monoclonal antibody; Passive immunization; PrPSc conformer; Prion protein; Proteostasis; Recycling propagation

Mesh:

Substances:

Year:  2018        PMID: 29987703      PMCID: PMC6326903          DOI: 10.1007/s12035-018-1208-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  61 in total

1.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.

Authors:  D Peretz; R A Williamson; K Kaneko; J Vergara; E Leclerc; G Schmitt-Ulms; I R Mehlhorn; G Legname; M R Wormald; P M Rudd; R A Dwek; D R Burton; S B Prusiner
Journal:  Nature       Date:  2001-08-16       Impact factor: 49.962

Review 2.  Shattuck lecture--neurodegenerative diseases and prions.

Authors:  S B Prusiner
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

3.  Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes.

Authors:  Salit Tzaban; Gilgi Friedlander; Oshrat Schonberger; Lior Horonchik; Yifat Yedidia; Gideon Shaked; Ruth Gabizon; Albert Taraboulos
Journal:  Biochemistry       Date:  2002-10-22       Impact factor: 3.162

4.  Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.

Authors:  M Enari; E Flechsig; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

Review 5.  Cellular biology of prion diseases.

Authors:  D A Harris
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

6.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

7.  Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

Authors:  F L Heppner; C Musahl; I Arrighi; M A Klein; T Rülicke; B Oesch; R M Zinkernagel; U Kalinke; A Aguzzi
Journal:  Science       Date:  2001-09-06       Impact factor: 47.728

Review 8.  Variant Creutzfeldt-Jakob disease.

Authors:  H J T Ward; M W Head; R G Will; J W Ironside
Journal:  Clin Lab Med       Date:  2003-03       Impact factor: 1.935

9.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs.

Authors:  Nathalie Daude; Mathieu Marella; Joelle Chabry
Journal:  J Cell Sci       Date:  2003-05-20       Impact factor: 5.285

Review 10.  Cell biological studies of the prion protein.

Authors:  D A Harris
Journal:  Curr Issues Mol Biol       Date:  1999       Impact factor: 2.081

View more
  6 in total

1.  Apolipoprotein E4 Effects a Distinct Transcriptomic Profile and Dendritic Arbor Characteristics in Hippocampal Neurons Cultured in vitro.

Authors:  Jenny R Diaz; Mitchell Martá-Ariza; Alireza Khodadadi-Jamayran; Adriana Heguy; Aristotelis Tsirigos; Joanna E Pankiewicz; Patrick M Sullivan; Martin J Sadowski
Journal:  Front Aging Neurosci       Date:  2022-04-29       Impact factor: 5.702

2.  Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology.

Authors:  Allal Boutajangout; Wei Zhang; Justin Kim; Wed Ali Abdali; Frances Prelli; Thomas Wisniewski
Journal:  Front Aging Neurosci       Date:  2021-02-25       Impact factor: 5.750

3.  Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.

Authors:  Luise Linsenmeier; Behnam Mohammadi; Mohsin Shafiq; Karl Frontzek; Julia Bär; Amulya N Shrivastava; Markus Damme; Feizhi Song; Alexander Schwarz; Stefano Da Vela; Tania Massignan; Sebastian Jung; Angela Correia; Matthias Schmitz; Berta Puig; Simone Hornemann; Inga Zerr; Jörg Tatzelt; Emiliano Biasini; Paul Saftig; Michaela Schweizer; Dmitri Svergun; Ladan Amin; Federica Mazzola; Luca Varani; Simrika Thapa; Sabine Gilch; Hermann Schätzl; David A Harris; Antoine Triller; Marina Mikhaylova; Adriano Aguzzi; Hermann C Altmeppen; Markus Glatzel
Journal:  Sci Adv       Date:  2021-11-24       Impact factor: 14.136

4.  Absence of Apolipoprotein E is associated with exacerbation of prion pathology and promotes microglial neurodegenerative phenotype.

Authors:  Joanna E Pankiewicz; Anita M Lizińczyk; Leor A Franco; Jenny R Diaz; Mitchell Martá-Ariza; Martin J Sadowski
Journal:  Acta Neuropathol Commun       Date:  2021-09-26       Impact factor: 7.578

5.  A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer.

Authors:  Sophie Mouillet-Richard; Séverine Martin-Lannerée; Delphine Le Corre; Théo Z Hirsch; Alexandre Ghazi; Marine Sroussi; Camilla Pilati; Aurélien de Reyniès; Fatima Djouadi; Nicolas Vodovar; Jean-Marie Launay; Pierre Laurent-Puig
Journal:  Oncogene       Date:  2022-08-12       Impact factor: 8.756

Review 6.  A New Take on Prion Protein Dynamics in Cellular Trafficking.

Authors:  Rodrigo Nunes Alves; Rebeca Piatniczka Iglesia; Mariana Brandão Prado; Maria Isabel Melo Escobar; Jacqueline Marcia Boccacino; Camila Felix de Lima Fernandes; Bárbara Paranhos Coelho; Ailine Cibele Fortes; Marilene Hohmuth Lopes
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.